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Background. Cancer is an important cause of morbidity and mortality in individuals infected with human im-
munodeficiency virus (HIV), but patterns of cancer incidence after combination antiretroviral therapy (ART) initia-
tion remain poorly characterized.
Methods. We evaluated the incidence and timing of cancer diagnoses among patients initiating ART between
1996 and 2011 in a collaboration of 8 US clinical HIV cohorts. Poisson regression was used to estimate incidence
rates. Cox regression was used to identify demographic and clinical characteristics associated with cancer incidence
after ART initiation.
Results. At initiation of first combination ART among 11 485 patients, median year was 2004 (interquartile
range [IQR], 2000–2007) and median CD4 count was 202 cells/mm3 (IQR, 61–338). Incidence rates for Kaposi
sarcoma (KS) and lymphomas were highest in the first 6 months after ART initiation (P < .001) and plateaued there-
after, while incidence rates for all other cancers combined increased from 416 to 615 cases per 100 000 person-years
from 1 to 10 years after ART initiation (average 7% increase per year; 95% confidence interval, 2%–13%). Lower
CD4 count at ART initiation was associated with greater risk of KS, lymphoma, and human papillomavirus–related
cancer. Calendar year of ART initiation was not associated with cancer incidence.
Conclusions. KS and lymphoma rates were highest immediately following ART initiation, particularly among
patients with low CD4 cell counts, whereas other cancers increased with time on ART, likely reflecting increased
cancer risk with aging. Our results underscore recommendations for earlier HIV diagnosis followed by prompt ART
initiation along with ongoing aggressive cancer screening and prevention efforts throughout the course of HIV care.
Keywords. HIV-associated malignancies; AIDS-defining cancer; non-AIDS-defining cancer; combination anti-
retroviral therapy.
While the distribution of cancer types within human
immunodeficiency virus (HIV)-infected populations
has changed due to advances in treatment and demo-
graphic changes, malignancies remain an important
cause of morbidity and mortality [1–4]. Cancer incidence
trends in the HIV population have been thoroughly ex-
amined across calendar time [1, 5–7].However, incidence
rates among HIV patients are not well described across
time relative to initiation of combination antiretroviral
therapy (ART), even though most cancers in developed
countries are diagnosed after ART initiation [8–10].
Given the many changes that can occur after ART
initiation, including immune reconstitution, HIV repli-
cation, aging, and ongoing exposure to carcinogens,
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cancer incidence over time following ART initiation is expected
to be dynamic. Additionally, improvements in access to HIV
testing and linkage to care as well as changes in the timing of
ART initiation may impact the timing and incidence of cancer
diagnoses in treated patients. In a large, diverse US cohort of
HIV-infected patients in care, the Centers for AIDS Research
(CFAR) Network of Integrated Clinical Systems (CNICS), we
evaluated trends in cancer incidence rates over time after ART
initiation to inform cancer screening and prevention efforts for
the HIV population in the ART era. We further identified
patient characteristics associated with these trends that may




We conducted this study in the CNICS cohort, which includes
>25 000 HIV-infected adults in routine care at 8 university-
affiliated CFARs from 1995 to the present. The methodology
and characteristics of the CNICS cohort are described in detail
elsewhere [11]. In brief, CNICS is a dynamic observational
cohort with approximately 1400 new patients enrolling and
13% of existing patients leaving care each year. CNICS captures
extensive and comprehensive electronic medical data, including
demographics, medications, comorbid diagnoses, and laborato-
ry values [11]. Diagnoses of cancer are verified through a stan-
dardized process, including detailed record abstraction and
adjudication of malignancies [12].
For our study, we included patients who initiated ART with a
known start date between 1 January 1996–30 August 2011, and
had a CD4 count and HIV RNA measurement at ART initia-
tion. Baseline CD4 count and HIV RNA measures were the
values most proximal to, but no more than 12 months before,
ART initiation. ART was defined as concurrent initiation of at
least 3 different antiretrovirals. For our primary analyses, we in-
cluded patients with prior exposure to 1 or 2 nucleoside/nucle-
otide agents (mono- and dual ART, respectively) or who had
an unknown antiretroviral history prior to initiating ART. We
did not analyze person-time prior to ART initiation; however,
we did assess effects of prior therapy exposure on our results,
and conducted sensitivity analyses in which only antiretroviral-
naive patients at ART initiation were included.
Patients were followed from ART initiation to the first of the
following: cancer diagnosis, death, loss to follow-up (defined as
12 months without a clinical visit), or administrative censoring
at the last date of cancer ascertainment for each clinic site
(range of 31 May 2010–31 August 2011). Follow-up time was
administratively censored at 10 years after ART initiation, at
which point <10% of the patients remained under observation.
Only the first cancer diagnosis after ART initiation was included
as an event. In our primary analyses, we included all patients
initiating ART without regard to cancer events prior to ART
initiation. To assess the influence of including patients with a
previous history of cancer, we performed sensitivity analyses in
which patients with cancer diagnoses prior to ART initiation
were excluded.
Statistical Analysis
Incidence rates (IRs) were estimated as the total number of
cancer diagnoses within a time interval divided by the total
number of person-years contributed within the same interval.
Overall cancer incidence rates and incidence rates within 6-
month and 1-year time intervals following ART initiation were
calculated for specific cancers as well as for clinically meaning-
ful predefined groups of cancers. Specifically, we assessed
incidence rates using different categorizations including AIDS-
defining cancers (ADCs; including Kaposi sarcoma [KS], non-
Hodgkin lymphoma, and cervical cancer); non-AIDS-defining
cancers (NADCs); lymphomas; human papillomavirus (HPV)–
related cancers (including cervical, anal, squamous cell oral
cavity/pharynx, vaginal/vulvar, and penile cancer); virus-related
Table 1 Demographic and Clinical Characteristics of 11 485
Patients Initiating Combination Antiretroviral Therapy in the Centers
for AIDS Research Network of Integrated Clinical Systems, 1996–
2011
Characteristic No. of Patients
Total 11 485
Female sex 2304 (20.1%)






Injection drug user 2156 (18.8%)
Men who have sex with men 6328 (55.1%)
Antiretroviral exposure prior to first ART 3207 (27.9%)




≥3 NRTIs 570 (5.0%)
NNRTI + PI 441 (3.8%)
Othera 196 (1.7%)
CD4 count, cells/mm3, median (IQR) 202 (61–338)
HIV RNA level, log10 copies/mL, median (IQR) 4.8 (4.3–5.3)
Abbreviations: ART, combination antiretroviral therapy; HIV, human immunodefi-
ciency virus; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Includes regimens with an integrase inhibitor, fusion inhibitor, or entry
inhibitor.
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cancers (including all ADCs, all HPV-related cancers, Hodgkin
lymphoma, and liver cancer); and virus-unrelated cancers.
Poisson regression was used to contrast incidence rates
between time intervals and to estimate trends in incidence rates
across time following ART initiation. Baseline clinical charac-
teristics were examined with Cox regression to identify predic-
tors of cancer incidence following ART initiation. Cancers were
grouped by common etiology and similar incidence patterns
over time when assessing associations with baseline characteris-
tics. Multivariable analyses were conducted with adjustment
for all baseline demographic and clinical predictors determined
to be associated with cancer incidence based on a priori
knowledge. Two separate adjustment sets were used: one with
CD4 count at ART initiation, and one with nadir CD4 count
any time prior to ART. These 2 variables were not included si-
multaneously as they were highly correlated, but were included
separately to examine whether choice of CD4 measure affected
other estimates differentially, especially for patients with prior
antiretroviral exposure. Incidence rates across time were also
stratified by CD4 count at ART initiation (≥200 or <200 cells/
mm3), age (≥45 or <45 years), and prior exposure to antiretro-
virals. Changes in the associations of these predictors with cancer
incidence were assessed visually and through the evaluation of
interaction terms with log(time) in regression models.
Table 2. Cancer Incidence Rates Within 10 Years After Combination Antiretroviral Therapy Initiation, Centers for AIDS Research
Network of Integrated Clinical Systems, 1996–2011
Incidence Rate per 100 000 Person-years (95% CI)
Cancer Type Total No. 0–10 y 0–6 mo 6 mo–10 y
Overall 457 987 (900–1081) 2405 (2030–2848) 793 (711–884)
ADC 241 515 (454–584) 1881 (1554–2278) 330 (279–390)
KS 143 304 (258–358) 1342 (1071–1683) 164 (129–208)
NHL non-CNS 76 161 (128–201) 357 (230–553) 134 (103–175)
NHL CNS 19 40 (26–63) 160 (84–308) 24 (13–44)
Cervicala 3 30 (10–92) . . . . . .
NADC 216 466 (408–533) 520 (362–749) 459 (398–530)
Virus-related NADCs 89 192 (156–237) 251 (149–424) 184 (147–231)
Squamous cell anal 32 69 (49–98) 72 (27–191) 69 (47–100)
Hodgkin lymphoma 27 58 (40–85) 144 (72–287) 47 (30–73)
Liver 17 37 (23–59) 18 (3–127) 39 (24–64)
Squamous cell oral cavity/pharynx 9 19 (10–37) . . . . . .
Otherb 4 9 (3–23) . . . . . .
Virus-unrelated NADCs 127 274 (230–326) 269 (162–447) 275 (228–331)
Lung 26 56 (38–82) 54 (17–167) 56 (38–85)
Prostatea 20 54 (35–83) 22 (3–159) 58 (37–91)
Breasta 13 128 (75–221) 177 (44–708) 122 (68–221)
Melanoma 10 22 (12–40) . . . . . .
Colorectal 8 17 (9–35) . . . . . .
Kidney 5 11 (5–26) . . . . . .
Otherc 45 93 (69–125) . . . . . .
Lymphomasd 122 259 (217–309) 660 (479–912) 205 (165–253)
HPV-related cancerse 48 104 (78–138) 108 (48–140) 103 (76–140)
Only overall incidence rates were calculated for cancer types with ≤10 cases.
Abbreviations: ADC, AIDS-defining cancer; CI, confidence interval; CNS, central nervous system; HPV, human papillomavirus; KS, Kaposi sarcoma; NADC, non-
AIDS-defining cancer; NHL, non-Hodgkin lymphoma.
a Cervical cancer and breast cancer incidence calculated only among women. Prostate cancer incidence calculated only among men.
b Other virus-related cancers include penile, vaginal, and vulvar.
c Other virus-unrelated cancers include bladder, brain, esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue,
stomach, testicular, uterus, or non–squamous cell oral cavity/pharynx.
d Lymphomas included NHL non-CNS, NHL CNS, and Hodgkin lymphoma.
e HPV-related cancers included cervical, squamous cell anal (which includes squamous cell anorectal cancer), squamous cell oral cavity/pharynx, penile, vaginal,
and vulvar cancer.
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RESULTS
Baseline Characteristics
Of 25 337 patients enrolled in CNICS at the time of this analy-
sis, 11 485 were observed to initiate ART between 1996 and
2011 at a CNICS site with pre-ART CD4 count and HIV RNA
levels available. Of these 11 485 patients, 20% were female, 43%
white, 41% black, and 11% Hispanic (Table 1). Median age at
ART initiation was 38 years (interquartile range [IQR], 32–45).
Median year of ART initiation was 2004 (IQR, 2000–2007),
and 28% of patients had exposure to antiretrovirals prior to
combination ART initiation. At ART initiation, median CD4
count was 202 cells/mm3 (IQR, 61–338 cells/mm3) and median
HIV RNA was 4.8 log10 copies/mL (IQR, 4.3–5.3 copies/mL).
Most patients initiated a protease inhibitor–based regimen
(47%) or a nonnucleoside reverse transcriptase inhibitor–based
regimen (42%). In addition, 5% initiated a triple-nucleos(t)ide
reverse transcriptase inhibitor regimen, 4% initiated a regimen
with a protease inhibitor and a nonnucleoside reverse tran-
scriptase inhibitor, and 2% initiated regimens with another
anchor drug, including an integrase inhibitor, fusion inhibitor,
or entry inhibitor. The median length of follow-up after ART
initiation was 3.1 years (IQR, 1.4–6.2 years), and 9.5% of pa-
tients remained in follow-up at 10 years post-ART.
Cancer Incidence and Timing
During the 46 318 person-years of follow-up after ART initia-
tion, 457 cancer diagnoses were observed with an incidence
rate (IR) of 987 cases per 100 000 person-years (95% confi-
dence interval [CI], 900–1081 cases per 100 000 person-years;
Table 2). The overall incidence of ADCs was similar to that of
NADCs (ADC IR, 515 per 100 000 person-years [95% CI, 454–
584 cases per 100 000 person-years]; NADC IR, 466 per 100 000
person-years [95% CI, 408–533 cases per 100 000 person-years]).
The most common ADC was KS with an IR of 304 per 100 000
person-years (95% CI, 258–358 cases per 100 000 person-years),
whereas the most common NADC was anal cancer with an IR of
69 per 100 000 person-years (95% CI, 49–98 cases per 100 000
person-years). Among women, the most common NADC was
breast cancer (IR, 128 per 100 000 person-years [95% CI, 75–221
cases per 100 000 person-years]).
The timing of cancer incidence after ART initiation differed
between cancer types. The incidence of KS was particularly high
within the first 6 months after ART initiation (IR, 1342 cases per
100 000 person-years [95% CI, 1071–1683 cases per 100 000
person-years]), but decreased dramatically thereafter (IR for
second 6 months, 348 per 100 000 person-years [95% CI, 219–
552 cases per 100 000 person-years]), and stabilized at a low rate
(IR for 6 months–10 years, 164 per 100 000 person-years [95%
Figure 1. Incidence of first cancer across time following initiation of combination antiretroviral therapy (ART), Centers for AIDS Research Network of
Integrated Clinical Systems, 1996–2011. After ART initiation, incidence rates were estimated in the first 6 months, the second 6 months, and every year
thereafter. The vertical lines extending from each incidence rate estimate represent the 95% confidence interval. Listed below the x-axis are the total
numbers of patients remaining in follow-up at the end of each year. Solid line with circles, Kaposi sarcoma incidence; dashed line with squares, lymphoma
incidence; dotted line with triangles, incidence of non-Kaposi sarcoma, nonlymphoma cancers. Abbreviations: ART, combination antiretroviral therapy; KS,
Kaposi sarcoma.
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CI, 129–208 cases per 100 000 person-years]) (Table 2, Figure 1).
The incidence of lymphomas (both Hodgkin and non-Hodgkin)
was also higher in the first 6 months after ART initiation (IR,
660 per 100 000 person-years [95% CI, 479–912 cases per
100 000 person-years]) compared to 6–12 months after ART ini-
tiation (IR, 269 per 100 000 person-years [95% CI, 160–455
cases per 100 000 person-years]), but the absolute change in inci-
dence was smaller than for KS. By contrast, the incidence of
other cancers appeared to increase with time after ART initia-
tion. The incidence of all non-KS, non-lymphoma cancers com-
bined increased by 7% each year from ART initiation (95% CI,
2%–13%; P = .009), from 416 to 615 cases per 100 000 person-
years in years 1 and 10 after ART initiation, respectively.
Predictors of Cancer Incidence and Time Modification of
Predictors
Several characteristics at the time of ART initiation were associat-
ed with subsequent cancer incidence. Older age increased risk
for all cancers except KS in bivariable analyses, and associations
appeared the same in multivariable analyses (Table 3). Nonlym-
phoma, HPV-unrelated NADCs were most strongly associated
with older age (adjusted hazard ratio [AHR] for 10-year diffe-
rence in age, 2.33 [95% CI, 1.97–2.74]). Associations of older age
with cancer risk were consistent throughout time following ART
initiation (P for interaction with time >.05 for all cancers).
CD4 count at ART initiation was also an independent pre-
dictor of cancer. In both bivariable and multivariable analyses,
lower CD4 count was associated with higher incidence of all can-
cer groups except the nonlymphoma, HPV-unrelated NADCs.
Lower CD4 count was a particularly strong predictor of KS (AHR
per 100 cells/mm3 increase, 0.63 [95% CI, .54–.73]). The pattern
of a high incidence of KS within the first 6 months followed by a
steep decline was only seen among those with a CD4 count
<200 cells/mm3 at ART initiation (Figure 2, P for interaction of
CD4 count with time = .002). By contrast, thosewith a CD4 count
≥200 cells/mm3 had low incidence of KS throughout time after
ART initiation (IR, 0.1 per 100 person-years [95% CI, .1–.2 cases
per 100 000 person-years]). Low CD4 count was also associated
with high incidence of lymphomas and HPV-related cancers,
but for these cancers, associations with CD4 count were consis-
tent across time (both P for interaction with time >.20; Figure 2).
Prior exposure to antiretrovirals was associated with higher
incidence of HPV-related cancer following ART initiation. This
association persisted even when nadir CD4 count was included
in the model in place of CD4 count at ART initiation. Across
all follow-up time, prior antiretroviral exposure was not associ-
ated with incidence of other cancers. However, patients with
prior antiretroviral exposure had a lower incidence of lympho-
ma compared to antiretroviral-naive patients in the first year
following ART initiation (AHR, 0.41 [95% CI, .19–.93]), but a
higher incidence after 1 year (P for interaction with time <.05;
Figure 3).
Other characteristics examined were weaker predictors of
cancer incidence. Higher level of HIV RNA pre-ART was asso-
ciated with higher KS incidence after adjusting for CD4 count,
but not with any other cancer. No statistically significant associ-
ations were found between calendar year of ART initiation and
incidence of any cancer in bivariable analysis. After accounting
for variables such as age and CD4 count at ART initiation,
there was no association between calendar year and any cancer
(Table 3). The lack of association was robust to parameteriza-
tion of calendar year as a continuous or categorical variable.
Table 3. Patient Characteristics at Combination Antiretroviral
Therapy Initiation Associated With Incidence of First Cancer
Stratified by Cancer Type, Centers for AIDS Research Network of
Integrated Clinical Systems, 1996–2011
Characteristic
Hazard Ratio (95% CI)
Bivariable Multivariablea
Kaposi sarcoma
Age at ART initiation (per 10-y
increase)
1.00 (.84–1.19) 0.99 (.82–1.21)
Calendar year of starting ART 1.03 (.99–1.07) 1.01 (.97–1.07)
Prior mono- or dual therapy 1.00 (.70–1.43) 1.34 (.91–1.99)
CD4 count, per 100 cells/mm3 0.64 (.56–.73) 0.63 (.54–.73)
Viral load, per log10 copies/mL 1.79 (1.42–2.27) 1.31 (1.01–1.70)
Lymphomas
Age at ART initiation, per 10-y
increase
1.29 (1.07–1.55) 1.30 (1.07–1.58)
Calendar year of starting ART 0.98 (.93–1.03) 0.97 (.91–1.02)
Prior mono- or dual therapy 0.95 (.64–1.41) 0.86 (.55–1.33)
CD4 count, per 100 cells/mm3 0.81 (.72–.91) 0.80 (.71–.91)
Viral load, per log10 copies/mL 1.07 (.85–1.36) 0.85 (.65–1.11)
HPV-related cancers
Age at ART initiation, per 10-y
increase
1.33 (.99–1.79) 1.41 (1.04–1.93)
Calendar year of starting ART 0.96 (.88–1.04) 1.00 (.91–1.10)
Prior mono- or dual therapy 2.33 (1.32–4.13) 2.67 (1.41–5.04)
CD4 count, per 100 cells/mm3 0.83 (.69–0.99) 0.80 (.65–0.97)
Viral load, per log10 copies/mL 1.13 (.78–1.65) 1.05 (.69–1.61)
Nonlymphoma, HPV-unrelated
NADCs
Age at ART initiation, per 10-y
increase
2.34 (2.01–2.74) 2.33 (1.97–2.74)
Calendar year of starting ART 1.01 (.96–1.06) 1.00 (.95–1.06)
Prior mono- or dual therapy 1.19 (.85–1.69) 1.15 (.78–1.70)
CD4 count, per 100 cells/mm3 0.99 (.91–1.07) 0.99 (.89–1.09)
Viral load, per log10 copies/mL 0.95 (.77–1.18) 0.93 (.73–1.19)
Abbreviations: ART, combination antiretroviral therapy; CI, confidence interval;
HPV, human papillomavirus; NADC, non-AIDS-defining cancer.
a Multivariable analyses adjusted for other covariates listed as well as Centers
for AIDS Research Network of Integrated Clinical Systems study site, sex/men
who have sex with men, race, and injection drug use.
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In sensitivity analysis where 489 patients with cancer diag-
noses prior to ART initiation were excluded, similar incidence
rates and incidence trends were observed and the same pre-
dictors of cancer incidence were identified (data not shown).
Similarly, our findings were consistent in a subset analysis con-
ducted among 8278 patients who were antiretroviral naive at
ART initiation. In this subset, cancer incidence rates and trends
were similar to the full study population, and factors associated
with higher risk were also consistent in both unadjusted and
adjusted analyses (data not shown).
DISCUSSION
This study of 11 485 patients from a multisite US clinical
cohort of HIV-infected patients revealed distinct patterns of
cancer incidence following ART initiation. This likely reflects
varying etiologic contributions of aging, immunosuppression,
and prior antiretroviral exposure, to the occurrence of specific
cancer types. By contrast, cancer incidence did not appear to
change over calendar time among ART initiators, suggesting
that the incremental improvements in ART regimens during
the modern ART era have not had dramatic effects on cancer
incidence.
The most dramatic change in incidence after ART initiation
was seen for KS, which had a higher incidence than all other
cancers combined in the first 6 months and a steep decline
thereafter. Notably, this pattern was seen exclusively in those
initiating ART with a CD4 count <200 cells/mm3. A similar
pattern has been noted in ART initiators in the Swiss HIV
Cohort Study [13]. The HIV/AIDS Cancer Match Study found
that severe immunosuppression at AIDS diagnosis was strongly
associated with risk of a new KS diagnosis in the 4–9 months
after AIDS diagnosis and less strongly thereafter [14]. This
finding and prior research demonstrating higher KS incidence
among those with lower current CD4 counts [8, 15–17] are
consistent with an early risk driven by more severe immuno-
suppression. In addition to severe immunosuppression in-
creasing the risk of KS development, these individuals are
more likely to experience more rapid immune reconstitution
that may unmask previously subclinical KS, a phenomenon re-
ferred to as immune reconstitution inflammatory syndrome
(IRIS) [18–21].
Figure 2. Cancer incidence across time following initiation of combination antiretroviral therapy (ART) stratified by CD4 count at ART initiation, Centers for
AIDS Research Network of Integrated Clinical Systems, 1996–2011. Graphs divided by cancer type: A, Kaposi sarcoma; B, lymphoma; C, human papillomavirus–
related cancer; D, other cancers. Dotted lines with diamonds, incidence rates among those with CD4 counts <200 cells/mm3 at ART initiation; dashed lines
with squares, incidence rates among those with CD4 counts ≥200 cells/mm3 at ART initiation. *Other cancer includes lung, liver, prostate, breast, melano-
ma, colorectal, kidney, bladder, brain, esophagus, larynx, leukemia, multiple myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue, stomach,
testicular, uterus, or non–squamous cell oral cavity/pharynx. Abbreviations: ART, combination antiretroviral therapy; HPV, human papillomavirus.
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Lymphomas showed a pattern similar to KS, but with a
lower incidence in the first 6 months and a more gradual de-
crease in incidence thereafter. A decrease in incidence after 6
monthswas seen forbothnon-Hodgkin lymphomaandHodgkin
lymphoma. Individuals with no prior antiretroviral exposure
and those with lower CD4 counts at ART initiation had higher
lymphoma incidence within the first 6 months. Similar to KS,
these patient groups may be more likely to develop lymphoma-
associated IRIS events after ART initiation. An IRIS effect for
lymphoma was hypothesized after a study in France showed a
similar incidence pattern when looking at Hodgkin lymphoma
after ART [22]. It is also possible that early symptoms of sub-
clinical KS or lymphoma may have led to the diagnosis of HIV
and prompt initiation of ART, with documentation of the de-
finitive cancer diagnosis shortly after starting ART. Although 1
lymphoma cases and 9 KS cases were observed within the first
week after ART initiation, these early cases do not completely
account for the higher incidence in the first 6 months. Regard-
less, these findings highlight the importance of early HIV diag-
nosis and timely ART initiation before individuals reach
advanced immunosuppression.
All other cancers combined showed an increasing trend over
time following ART initiation with a lower incidence within the
first 6 months and a significant trend toward higher incidence
over time. This increase is likely a consequence of increasing
cancer incidence with advancing age, as noted in the general
population. Within this group of cancers that excluded KS and
lymphoma, HPV-related cancers showed a strong association
with CD4 count at ART initiation and higher incidence in
those with prior ARV exposure, which may reflect longer dura-
tion of HIV infection. As HIV infection can increase the risk of
HPV infection, lag time may occur before the increased risk is
manifested as increased cancer diagnosis rates in patients with
a longer duration of HIV infection [23–26]. It is also possible
that adjustment for nadir CD4, a risk factor for HPV-associated
cancers [7, 9, 26, 27], was inadequate if patients with prior anti-
retroviral exposure experienced their nadir CD4 before entry
into a CNICS clinic. We did not observe an association
between CD4 count at ART initiation and incidence of cancers
that are neither AIDS-defining or associated with viral infec-
tions. Others have shown some virus-unrelated NADCs to
be associated with the extent of immunosuppression [16, 28].
Figure 3. Cancer incidence across time following initiation of combination antiretroviral therapy (ART) stratified by antiretroviral history at ART initiation,
Centers for AIDS Research Network of Integrated Clinical Systems, 1996–2011. Graphs divided by cancer type: A, Kaposi sarcoma; B, lymphoma; C,
human papillomavirus–related cancer; D, other cancers. Dotted lines with diamonds, incidence rates among those who were antiretroviral naive at ART ini-
tiation; dashed lines with squares, incidence rates among those with prior exposure to mono- or dual therapy or an unknown antiretroviral history at ART
initiation. *Other cancer includes lung, liver, prostate, breast, melanoma, colorectal, kidney, bladder, brain, esophagus, larynx, leukemia, multiple
myeloma, ovary, pancreas, peritoneum, small intestine, soft tissue, stomach, testicular, uterus, or non–squamous cell oral cavity/pharynx. Abbreviations:
ART, combination antiretroviral therapy; ARV, antiretroviral; HPV, human papillomavirus.
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A larger sample size may be needed to observe an association
between low CD4 count and virus-unrelated NADCs; however,
our data suggest that the relationship is not particularly strong.
Previous studies have described changing trends in cancer
incidence within the HIV population as a whole [5, 7, 29];
however, in our population of ART initiators no changes in
cancer incidence were observed over calendar time. Our study
included more recent calendar years of follow-up than previous
studies, and 75% of patients initiated ART in the year 2000 or
later. Trends identified in the larger HIV population are likely
indicative of increased uptake of ART, whereas more recent
changes in the potency or durability of first-line ART regimens [30]
may have little impact on cancer incidence. This emphasizes
the continued need for cancer screening and prevention mea-
sures in the HIV population, regardless of continued improve-
ments in ART. For instance, increased HPV vaccination and
anal pap smear screening may help prevent anal cancer, one of
the most common malignancies in this population.
Our sample size was considerable; however, there were not
enough incident cancer cases to conduct separate analyses for all
specific cancer types. Although we aimed to categorize cancers in
etiologically meaningful ways, there may be differing trends for
cancers grouped together that were undetectable in our study,
particularly within the heterogeneous group of nonlymphoma,
non-HPV-related NADCs. Additionally, even within specific
cancer types, malignancies may have different etiologic origins.
Such is the case with oral cavity/pharynx cancers and non-
Hodgkin lymphomas, in which only a proportion are linked to
viral coinfection (HPV and Epstein-Barr virus, respectively).
Despite this limitation, such groupings were necessary to discern
meaningful trends and associations and can be used to guide
more detailed analyses in the future.
This study was notable for the following strengths: (1) a large
and representative HIV-infected clinical population; (2) de-
tailed laboratory and antiretroviral information; and (3) well-
validated cancer diagnoses. The current study does not account
for changes or discontinuations in ART after initiation, nor
does it account for differences in the immunologic or virologic
response to ART. In a future study we will examine how these
changes after ART initiation may impact cancer incidence to
expand on these findings and further our understanding of
cancer incidence trends over time in this population.
We showed distinct patterns of cancer incidence after ART
initiation that differed by cancer type and were modified by
several baseline patient characteristics. These findings highlight
the importance of cancer screening and cancer prevention efforts
throughout the course of HIV clinical care for those cancers for
which evidence-based interventions exist. Currently, robust
cancer screening and prevention guidelines have not been estab-
lished that address the specific needs of HIV-infected individuals.
Within the first year after ART initiation, KS and lymphomas are
the largest sources of cancer morbidity. After the first year of
ART initiation, HPV-associated cancer (particularly anal cancer)
and other NADCs become more common. These results suggest
that screening for HPV-associated cancers and certain NADCs
should be prioritized once patients are on stable ART.
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